

ASX Announcement

Preclinical & Clinical Programs Update

30 September 2021 – Race Oncology Limited (“Race”) wishes to share an update on our clinical and preclinical programs. This was committed to in the Expected News commentary in our June 2021 Quarterly report (ASX Announcement: 29 July 2021). While COVID related health and safety restrictions in NSW have slowed some programs we continue to make significant progress in Australia and internationally.

Pillar 1

Race shared interim results of our collaborative melanoma pre-clinical program with the University of Newcastle (ASX Announcement: 30 September 2021). Zantrene[®] (bisantrone dihydrochloride) was shown at low concentrations to kill high FTO producing melanoma cancer cells. Furthermore, sensitivity to Zantrene correlates with FTO levels, where high FTO producing cells show up to 60x greater sensitivity than low FTO producing cells.

Our preclinical clear cell renal cell carcinoma and extramedullary AML programs under the supervision of Associate Professor Nikki Verrills are progressing despite COVID-related restrictions on lab personnel at the University of Newcastle. Race expects to be able to provide interim updates to investors on both programs in early Q4 CY 2021.

Pillar 2

Significant advances have been made with Race’s collaborative preclinical project to explore Zantrene’s low cardiotoxicity at the molecular level, led by eminent cardiotoxicity researchers, Associate Professors Aaron Sverdlov and Doan Ngo of the University of Newcastle. Race expects to be able to provide an interim update on this program to our shareholders in Q4 2021.

The results of this study will support a possible Phase 2b human trial of Zantrene in anthracycline naïve breast cancer patients. These trials are currently being explored for feasibility in Europe, with potential for initiation in 2022.

Pillar 3

Race shared that the first patient was dosed in the Phase 1b/2 AML trial (ASX announcement: 9 August 2021). This trial is using Zantrene in combination with fludarabine and clofarabine to treat relapsed/refractory (R/R) Acute Myeloid Leukaemia. The study is being led by Professor Arnon Nagler of the Chaim Sheba Medical Center, Israel, who previously conducted the Phase 2 single agent Zantrene R/R AML trial which demonstrated a 40% clinical response.

The trial is recruiting patients in line with expectations. Race will update investors on further progress upon completion of the Phase 1b dose finding stage.

Progress on our Australian extramedullary AML focused Phase 2 trial is continuing with the close support of the Contract Research Organisation (CRO), Parexel (ASX Announcement: 2 June 2021). While COVID-19 restrictions in New South Wales (Australia) have impeded progress for this trial, Race expects to submit the application for human ethics approval in Q4 2021.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. The Company also has compelling clinical data for the use of Bisantrone as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of Zantrene.

Learn more at www.raceoncology.com.

Release authorised by:

Phil Lynch, CEO/MD on behalf
of the Race Board of Directors
phillip.lynch@raceoncology.com

Media contact:

Jane Lowe
+61 411 117 774
jane.lowe@irdepartment.com.au